ERBB2 and breast carcinoma: Buzdar et al (2005, 2007) and Gianni (2008) reported the results of randomised trials of trastuzumab given with neoadjuvant chemotherapy to patients with HER2-positive breast cancer, and the pCR rate was significantly higher than that in the control arm.